Farawela Hala M, Khorshied Mervat M, Kassem Neemat M, Kassem Heba A, Zawam Hamdy M
Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt.
J Cancer Res Clin Oncol. 2014 Aug;140(8):1323-30. doi: 10.1007/s00432-014-1694-3. Epub 2014 May 8.
Multidrug resistance (MDR1) represents a major obstacle in the chemotherapeutic treatment of acute leukemia (AL). Adenosine triphosphate ATP-binding cassette (ABCB5) and MDR1 genes are integral membrane proteins belonging to ATP-binding cassette transporters superfamily.
The present work aimed to investigate the impact of ABCB5 and MDR1 genes expression on the response to chemotherapy in a cohort of Egyptian AL patients. The study included 90 patients: 53 AML cases and 37 ALL cases in addition to 20 healthy volunteers as controls.
Quantitative assessment of MDR1 and ABCB5 genes expression was performed by quantitative real-time polymerase chain reaction. Additional prognostic molecular markers were determined as internal tandem duplications of the FLT3 gene (FLT3-ITD) and nucleophosmin gene mutation (NPM1) for AML cases, and mbcr-abl fusion transcript for B-ALL cases.
In AML patients, ABCB5 and MDR1 expression levels did not differ significantly between de novo and relapsed cases and did not correlate with the overall survival or disease-free survival. AML patients were stratified according to the studied genetic markers, and complete remission rate was found to be more prominent in patients having low expression of MDR1 and ABCB5 genes together with mutated NPM1 gene. In ALL patients, ABCB5 gene expression level was significantly higher in relapsed cases and MDR1 gene expression was significantly higher in patients with resistant disease.
In conclusion, the results obtained by the current study provide additional evidence of the role played by these genes as predictive factors for resistance of leukemic cells to chemotherapy and hence treatment outcome.
多药耐药(MDR1)是急性白血病(AL)化疗治疗中的主要障碍。三磷酸腺苷ATP结合盒(ABCB5)和MDR1基因是属于ATP结合盒转运蛋白超家族的整合膜蛋白。
本研究旨在调查ABCB5和MDR1基因表达对一组埃及AL患者化疗反应的影响。该研究包括90名患者:53例急性髓系白血病(AML)病例和37例急性淋巴细胞白血病(ALL)病例,另外20名健康志愿者作为对照。
通过定量实时聚合酶链反应对MDR1和ABCB5基因表达进行定量评估。对于AML病例,确定其他预后分子标志物为FLT3基因的内部串联重复(FLT3-ITD)和核磷蛋白基因突变(NPM1),对于B-ALL病例,确定为mbcr-abl融合转录本。
在AML患者中,ABCB5和MDR1的表达水平在初发和复发病例之间无显著差异,且与总生存期或无病生存期无关。根据所研究的基因标志物对AML患者进行分层,发现MDR1和ABCB5基因低表达且NPM1基因突变的患者完全缓解率更高。在ALL患者中,ABCB5基因表达水平在复发病例中显著更高,MDR1基因表达在耐药患者中显著更高。
总之,本研究获得的结果为这些基因作为白血病细胞对化疗耐药及治疗结果的预测因素所起的作用提供了更多证据。